BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19899005)

  • 1. Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer.
    Pinkawa M; Piroth MD; Fischedick K; Holy R; Klotz J; Nussen S; Krenkel B; Eble MJ
    Strahlenther Onkol; 2009 Nov; 185(11):724-30. PubMed ID: 19899005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.
    Norkus D; Miller A; Kurtinaitis J; Haverkamp U; Popov S; Prott FJ; Valuckas KP
    Strahlenther Onkol; 2009 Nov; 185(11):715-21. PubMed ID: 19899003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of treatment volumes and techniques in prostate cancer radiation therapy.
    Lee CT; Dong L; Ahamad AW; Choi H; Cheung R; Lee AK; Horne DF; Breaux AJ; Kuban DA
    Am J Clin Oncol; 2005 Dec; 28(6):618-25. PubMed ID: 16317275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison.
    Pinkawa M; Piroth MD; Holy R; Fischedick K; Klotz J; Székely-Orbán D; Eble MJ
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):23-8. PubMed ID: 20832182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Life Changes >10 Years After Postoperative Radiation Therapy After Radical Prostatectomy for Prostate Cancer.
    Leufgens F; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):382-388. PubMed ID: 31201895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.
    Michalski JM; Bae K; Roach M; Markoe AM; Sandler HM; Ryu J; Parliament MB; Straube W; Valicenti RK; Cox JD
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):14-22. PubMed ID: 19577865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
    Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
    Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects.
    Rijkhorst EJ; Lakeman A; Nijkamp J; de Bois J; van Herk M; Lebesque JV; Sonke JJ
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1254-60. PubMed ID: 19857789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.
    Kupelian PA; Reddy CA; Klein EA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):988-93. PubMed ID: 11704322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-grade toxicity after conformal radiation therapy for prostate cancer--impact of bladder volume.
    Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Eble MJ
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):835-41. PubMed ID: 16289911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
    Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose-Rate Brachytherapy Combined With Ultrahypofractionated Radiation Therapy for Clinically Localized, Intermediate-Risk Prostate Cancer: Results From a Prospective Trial.
    Kollmeier MA; McBride S; Varghese M; Debonis D; Zhang Z; Cohen G; Damato AL; Mychalczak B; Gewanter R; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):905-913. PubMed ID: 32505609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy.
    Choudhury A; Arthur C; Malik J; Mandall P; Taylor C; Alam N; Tran A; Livsey J; Elliott T; Davidson S; Logue JP; Wylie J
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):661-7. PubMed ID: 25027670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure. A potential for increasing the benefit/risk ratio.
    Hille A; Töws N; Schmidberger H; Hess CF
    Strahlenther Onkol; 2005 Dec; 181(12):789-95. PubMed ID: 16362789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.